Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で1134.51%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 2.79Mに達しています。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD です。
適正水準
同社の最新のPEは-0.24で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は3.52M株で、前四半期比で23.92%増加しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.84です。